Resources/
Phil Blog

Editor’s Note: Biosimilar drugs hold tremendous potential for a wide variety of healthcare stakeholders including patients, providers, insurers, and the manufacturers of such products. However, these innovative therapies can only reach their full potential if they get and stay in the hands of patients that can afford them and utilize them appropriately. However, as many of these therapies find themselves in crowded categories and going to market with list prices that are still significant by any stretch, they face similar hurdles that their branded peers face as payers demand rebates and look to remain in pharmacy spend

A common challenge for specialty and specialty-lite brand commercialization teams is maximizing prescription coverage while minimizing free goods program overutilization. Patient bridge and quickstart programs, which provide temporary access to medications for patients experiencing coverage gaps or delays, are essential for therapy continuity and preventing financial burden on patients. However, these programs can negatively impact the manufacturers’ bottom line if manufacturers don’t implement the appropriate safeguards and requirements

SAN FRANCISCO, Calif. – June 6, 2023 – Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with Teva Pharmaceuticals that will make Digihaler® products available for prescription using the PhilRx Patient Access Platform. Teva’s Digihaler system is the first and only smart inhaler system that can provide objective inhaler data to help patients and their doctors have informed treatment discussion in support of asthma management

Editor’s Note: Predictive analytics has the potential to revolutionize not only care delivery, but also life sciences commercialization. However, this potential can only be realized if life sciences organizations integrate the right data and work with organizations skilled in applying predictive models that can generate actionable insights for field, brand, and patient services teams. While integrating prescription journey data into go to market strategies is not novel or even innovative, most organizations still struggle to generate actionable insights that can improve patient outcomes and drive business growth

Getting an innovative prescription drug approved for patient use is a significant milestone – however, it's only the beginning and certainly does not ensure the brand's commercial success. Considering it typically takes ten years and over $2.6 billion for a life sciences manufacturer to move a drug from its initial discovery into the marketplace, commercialization teams must employ effective launch strategies that differentiate their brand to get it into the hands of patients. Launching into a category with generic alternatives presents a unique challenge because payers often limit patients' access to the new entrant through utilization management tools that favor the lower-cost generics